RecruitingNCT04122872

GISAR German Interdisciplinary Sarcoma Registry

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Enrollment

9,000 participants

Start Date

Nov 29, 2018

Study Type

OBSERVATIONAL

Conditions

Sarcoma Sarcoma,Soft Tissue Sarcoma of Bone Carcinosarcoma

Summary

GISAR has an open and modular setup. It is sought to include as many German sarcoma and CS patients (i.e. sarcoma and CS patients treated in Germany) in the registry as possible. A basic data set should be collected on every included patient). In order to adress specific scientific questions, additionally detailed data can be collected in defined patient groups (e.g. effectiveness / adverse effects of systemic therapies in defined situations) within the context of sub-project add-on modules. This data collection can be prospective or retrospective depending on the sub-project

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building a national registry in Germany for patients with bone and soft tissue sarcomas — rare, aggressive cancers of the bone, muscle, and connective tissue. The goal is to collect comprehensive data to improve understanding and treatment of these cancers. **You may be eligible if...** - You are 18 years old or older - You have a confirmed diagnosis of a bone or soft tissue sarcoma, or a related tumour with borderline or unclear features (such as giant cell tumour of the bone, desmoid tumour, or atypical lipomatous tumour) - OR you have a sarcomatoid carcinoma or carcinosarcoma (a tumour with both cancer and sarcoma features) - You have signed an informed consent form **You may NOT be eligible if...** - There are no exclusion criteria — the registry is open to all eligible patients Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(21)

Universitätsklinikum Tübingen

Tübingen, Baden-Wurttemberg, Germany

Universitätsklinikum Erlangen

Erlangen, Bavaria, Germany

HELIOS Klinikum Bad Saarow

Bad Saarow, Germany

HELIOS Klinikum Berlin-Buch

Berlin, Germany

Vivantes Klinikum Berlin-Spandau

Berlin-Spandau, Germany

Universitätsklinikum Erlangen

Erlangen, Germany

Klinikum Frankfurt Höchst

Frankfurt, Germany

Krankenhaus Nordwest KHNW

Frankfurt, Germany

Uniklinik Freiburg

Freiburg im Breisgau, Germany

Universitätsmedizin Göttingen

Göttingen, Germany

Universitätsmedizin Greifswald

Greifswald, Germany

University Hospital Halle (Saale)

Halle, Germany

Asklepios Klinik St. Georg

Hamburg, Germany

Uniklinikum Leipzig

Leipzig, Germany

Universitätsmedizin Mainz

Mainz, Germany

Chirurgische Universitätsklinik Mannheim

Mannheim, Germany

Westfälische Wilhelms-Universität Münster

Münster, Germany

Klinikum Nürnberg

Nuremberg, Germany

Barmherzige Brüder Regensburg

Regensburg, Germany

Uniklinikum Regensburg

Regensburg, Germany

Universitätsklinikum Würzburg

Würzburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04122872

Related Trials

DESTINY-PANTUMOUR04

NCT0712400017 locations

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

NCT046057701 location

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

A Study of CRD3874-SI in People With Solid Tumors

NCT060216267 locations

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

NCT023907521 location